HAISCO PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.87 CNY | +0.06% |
|
+2.22% | +33.35% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 4.02B 555M | Sales 2025 * | 5.11B 707M | Capitalization | 34.06B 4.71B |
|---|---|---|---|---|---|
| Net income 2024 * | 466M 64.41M | Net income 2025 * | 617M 85.29M | EV / Sales 2024 * | 8.48 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 6.66 x |
| P/E ratio 2024 * |
74
x | P/E ratio 2025 * |
55.8
x | Employees | 5,448 |
| Yield 2024 * |
0.1% | Yield 2025 * |
0.26% | Free-Float | 21.39% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.69% | ||
| 1 week | +2.15% | ||
| Current month | +1.61% | ||
| 1 month | +19.07% | ||
| 3 months | +32.29% | ||
| 6 months | +29.79% | ||
| Current year | +33.26% |
1 week
29.88
31.86
1 month
25.5031.86
Current year
18.5931.86
1 year
18.5931.86
3 years
12.9331.86
5 years
11.5031.86
10 years
9.4339.50
| Managers | Title | Age | Since |
|---|---|---|---|
Xiu Lian Fan
CEO | Chief Executive Officer | 61 | 06-12-31 |
Peng Duan
DFI | Director of Finance/CFO | 49 | 16-10-20 |
Jun Min Wang
CHM | Chairman | 56 | 06-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jun Min Wang
CHM | Chairman | 56 | 06-12-31 |
Wei Zheng
BRD | Director/Board Member | 54 | 06-12-31 |
Xiu Lian Fan
CEO | Chief Executive Officer | 61 | 06-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 30.87 | +0.06% | 2 121 828 |
| 24-05-20 | 30.85 | -1.69% | 3,989,557 |
| 24-05-17 | 31.38 | +2.48% | 3,862,576 |
| 24-05-16 | 30.62 | -0.68% | 3,722,354 |
| 24-05-15 | 30.83 | +2.05% | 3,041,100 |
End-of-day quote Shenzhen S.E., May 19, 2024
More quotes
Haisco Pharmaceutical Group Co.,Ltd., formerly Xizang Haisco Pharmaceutical Group Co., Ltd., is a China-based company principally engaged in the research, development, manufacture and sale of new drugs and high-end medical instrument. The Companyâs main products are categorized into small volume injections, big volume injections, freeze-dried powder injections and others, which include polyene phosphatidylcholine injections, lipid solubility vitamins injection series, doradiazine methanesulfonate injections, nalmefene hydrochloride injections, fluprofen tromethamine tablets and cefoperazone sodium tazobactam sodium for injections, among others. The Company distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-15
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
30.85
CNY
Average target price
36.19
CNY
Spread / Average Target
+17.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +33.26% | 4.71B | |
| +34.35% | 705B | |
| +31.18% | 583B | |
| -3.49% | 364B | |
| +20.15% | 332B | |
| +6.19% | 291B | |
| +15.26% | 238B | |
| -3.72% | 210B | |
| +10.19% | 209B | |
| +9.21% | 169B |
- Stock Market
- Equities
- 002653 Stock
